© 2008, Columbia Laboratories, Inc. All rights reserved.

 

Please note that the product information provided on this website is intended only for residents of the United States.

Versus IM progesterone—

 

A Decade of Uncompromised Luteal Support,

Consistently Patient Preferred

 

In 12 studies, the efficacy of Crinone 8% was found to be comparable with IM progesterone. When patient preference was assessed, patients consistently preferred Crinone 8% to IM progesterone.

 

Click on the Lead Author’s name for more information about each study.

 

Berger B1

Fertil Steril, 2008

Schoolcraft WB7

Hum Reprod, 2000

Yanushpolsky E2

Fertil Steril, 2008

Saucedo LLE8

Fertil Steril, 2000

Saucedo LLE3

ESHRE,* 2003

Williams SC9

Fertil Steril, 2000

Anserini P4

Minerva Ginecol, 2001

Levine H10

J Soc Gynecol Investig, 2000

Coutifaris C5

Fertil Steril, 2000

Chantilis SJ11

Fertil Steril, 1999

Alper MM6

ESHRE, 2000

Gibbons WE12

Fertil Steril, 1998

*ESHRE=European Society for Human Reproduction and Embryology.

 

References: 1. Berger B, Phillips JA. A retrospective analysis of pregnancy outcomes in recipients of anonymously donated oocytes at a large ART center. Fertil Steril. 2008;89:S11–S12. 2. Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein MD. Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertil Steril. 2008;89:485–487. 3. Saucedo LLE, Batiza V, Arenas L, et al. Progesterone for luteal support: randomized, prospective trial comparing vaginal and i.m. administration. Paper presented at the 19th Annual Meeting of the European Society for Human Reproduction & Embryology; July 2003; Madrid, Spain. Abstract P-383. 4. Anserini P, Costa M, Remorgida V, Sarli R, Guglielminetti E, Ragni N. Luteal phase support in assisted reproductive cycles using either vaginal (Crinone 8) or intramuscular (Prontogest) progesterone: results of a prospective, randomized study [in Italian]. Minerva Ginecol. 2001;53:297–301. 5. Coutifaris C, Patrizio P, Schafer D, Bunso S, Bucci J, Barnhart K. Is the use of Crinone for support of the luteal phase detrimental to pregnancy outcome after transfer of non-cryopreserved embryos in good prognosis patients? A preliminary report. Fertil Steril. 2000;74(suppl 1):S205. Abstract P-350. 6. Alper MM, Penzias AS. Crinone® offers excellent implantation rates in patients undergoing IVF. Paper presented at the 16th Annual Meeting of the European Society for Human Reproduction & Embryology; June 2000; Bologna, Italy. Abstract P-059. 7. Schoolcraft WB, Hesla JS, Gee MJ. Experience with progesterone gel for luteal support in a highly successful IVF programme. Hum Reprod. 2000;15:1284–1288. 8. Saucedo LLE, Galache VP, Hernández AS, Santos HR, Arenas ML, Patrizio P. Randomized trial of three different forms of progesterone supplementation in ART: preliminary results. Fertil Steril. 2000;74(suppl 1):S150. Abstract P-175. 9. Williams SC, Donahue J, Muasher SJ. Vaginal progesterone therapy during programmed cycles for frozen embryo transfer: an analysis of serum progesterone levels and pregnancy rates. Fertil Steril. 2000;74(suppl 1):S209. Abstract P-363. 10. Levine H. Luteal support from the vaginal progesterone (P) gel Crinone 8%: preliminary results of multicenter trial show higher pregnancy rates than historical controls. J Soc Gynecol Investig. 2000;7(suppl). Abstract 571. 11. Chantilis SJ, Zeitoun KM, Patel SI, et al. Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles. Fertil Steril. 1999;72:823–829. 12. Gibbons WE, Toner JP, Hamacher P, Kolm P. Experience with a novel vaginal progesterone preparation in a donor oocyte program. Fertil Steril. 1998;69:96–101.